On a target area based analysis, the overall detection rate of any PCa was 54.1%, with non-significant differences between groups (51.5 vs 48.5, for the CAD assisted and MRI only FPB, respectively p[0.45). Similarly, overall cs PCa detection rate was 29.5%, with comparable outcomes between groups (29.8% vs 29.2%, respectively p[0.98). After stratifying for PI-RADS score, the use of CAD did not impact significantly on diagnosis (all p>0.05). A subgroup of FBP in transitional zone lesions, detection rate of csPCa was significantly higher in the cohort of CAD assisted procedures (54.5%vs11.1%, respectively p[0.028).
INTRODUCTION AND OBJECTIVES:
To avoid overdiagnosis and to optimize detection of clinically significant prostate cancer (csPCa, defined as Gleason 7), a risk-adapted detection strategy with follow-up intervals of two to eight years depending on initial PSA level and age is recommended (figure). Our aim was to review these recommendations using the long-term PCa detection and mortality rates of the well-known ERSPC cohort, applying a predominantly 4-year screening interval.
METHODS: We retrospectively assessed (cs)PCa incidence and (disease specific) mortality of 58,771 men (aged 50-70) who, at least, attended one screening visit within ERSPC. Biopsy indication was a PSA 3.0 ng/ml. Results are depicted by PSA level and age group at time of first screening.
RESULTS: Median follow-up was 13.5 yr. In men aged 50-59 and a PSA < 1.0 ng/ml at time of 1st screening 45.3% of PCa detected is csPCa. For men with an initial PSA of 3.0 ng/ml this percentage is 24.2%. Similar data for men aged 60-70 yr are 46% and 27.6%, i.e. with rising baseline PSA value the percentage of csPCa decreases pointing towards overdiagnosis due to more intensive screening (repeatedly using a purely PSA driven biopsy protocol). The time from initial screening to detection, ranging from 1.6 to 13.6 yr (caused by screening interval and a purely PSA based biopsy indication) is inversely proportional to the time from diagnosis to death. The percentage of PCa deaths among those PCa patients who died is in the range of 20 to 25 % (except one outlier in age 60-69 yr with baseline PSA < 1.0 yr) indicating that a) despite immediate and repeated screening about a quarter of PCa patients die from their disease and b) potential under treatment in men diagnosed at an elderly age. The chance of dying from PCa in men with low baseline values is however very rare.
CONCLUSIONS: Longer screening intervals together with a purely PSA driven biopsy algorithm will always result in men with potentially deadly disease slipping through the net. This is confirmed in other long term PCa screening data. However, more intense PSA based screening results in overdiagnosis. Considering the low number of events in men with low baseline PSA values the current recommendations seem to be in place. Selective detection of aggressive PCa, also at an elderly age and at the same time avoiding overdiagnosis should remain the ultimate goal in PCa early detection. 
PD64-03 TREXIT -A YEAR ON. MAKING A CLEAN BREAK FROM TRANS-RECTAL PROSTATE BIOPSY
Luke Stroman*, Anoushka Neale, Oussama El Hage, Paul Cathcart, Ben Challacombe, Ben Namdarian, Tim O'Brien, Rick Popert, London, United Kingdom INTRODUCTION AND OBJECTIVES: Trans-rectal (TRUS) prostate biopsy carries a risk of triggering sepsis. This risk is lower with trans-perineal (TP) approaches but logistic issues have limited uptake of TP biopsy by urologists. On 1st September 2017 at Guy's Hospital in London, we declared our intention to move to a prostate biopsy pathway involving only TP approaches. We termed this day, TREXIT, viz, a complete & clean break from trans-rectal prostate biopsy.
We hypothesised that our strategy might be successful if we could minimise the need for general anaesthetic (GA) and maximise utilisation of freehand TP biopsies performed under local anaesthetic (LA) or IV sedation (IVS).
METHODS: All consecutive patients undergoing TP biopsy over a one year time period were analysed. TP Biopsies were done either using a cognitive freehand technique using PrecisionpointTM transperineal access system or stepper with or without MRI fusion technology. A single pre-operative dose of antibiotics was given depending on trust protocol and patient allergies. Approach, anaesthetic methods and complications were gathered retrospectively from electronic patient records, morbidity and mortality meetings and A&E attendances.
RESULTS 
